Zhejiang Jingxin Pharmaceutical Co., Ltd.

SZSE:002020 Rapport sur les actions

Capitalisation boursière : CN¥10.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zhejiang Jingxin Pharmaceutical Croissance future

Future contrôle des critères 1/6

Zhejiang Jingxin Pharmaceutical is forecast to grow earnings and revenue by 13.5% and 12.9% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 12.8% in 3 years.

Informations clés

13.5%

Taux de croissance des bénéfices

13.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices18.8%
Taux de croissance des recettes12.9%
Rendement futur des capitaux propres12.8%
Couverture par les analystes

Low

Dernière mise à jour16 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Has Announced A Dividend Of CN¥0.30

May 21
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Has Announced A Dividend Of CN¥0.30

Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit

Apr 08
Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit

We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Mar 29
We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Prévisions de croissance des bénéfices et des revenus

SZSE:002020 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20265,7709559781,2005
12/31/20255,0137996591,0355
12/31/20244,431684N/A8335
6/30/20244,212705546856N/A
3/31/20244,099639608947N/A
12/31/20233,999619273793N/A
9/30/20233,905663205675N/A
6/30/20233,844681534995N/A
3/31/20233,870676463885N/A
1/1/20233,780662340856N/A
9/30/20223,705645192914N/A
6/30/20223,613630-127580N/A
3/31/20223,480616-252463N/A
1/1/20223,467613-33373N/A
9/30/20213,384720-127176N/A
6/30/20213,3447089377N/A
3/31/20213,322691131471N/A
12/31/20203,258653179513N/A
9/30/20203,287404213598N/A
6/30/20203,42942085424N/A
3/31/20203,547485247588N/A
12/31/20193,647520198535N/A
9/30/20193,507517433686N/A
6/30/20193,394482482675N/A
3/31/20193,194413283542N/A
12/31/20182,944369270523N/A
9/30/20182,906356317510N/A
6/30/20182,629307199381N/A
3/31/20182,384279N/A346N/A
12/31/20172,219264N/A385N/A
9/30/20172,071248N/A141N/A
6/30/20171,982231N/A339N/A
3/31/20171,936213N/A233N/A
12/31/20161,875200N/A253N/A
9/30/20161,735222N/A259N/A
6/30/20161,613209N/A168N/A
3/31/20161,502186N/A158N/A
12/31/20151,416166N/A145N/A
9/30/20151,362158N/A168N/A
6/30/20151,335143N/A169N/A
3/31/20151,294123N/A230N/A
12/31/20141,235107N/A210N/A
9/30/20141,183102N/A190N/A
6/30/20141,11290N/A175N/A
3/31/20141,03175N/A175N/A
12/31/201397464N/A111N/A
9/30/201391260N/A84N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 002020's forecast earnings growth (13.5% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 002020's earnings (13.5% per year) are forecast to grow slower than the CN market (21.9% per year).

Croissance élevée des bénéfices: 002020's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 002020's revenue (12.9% per year) is forecast to grow slower than the CN market (13.4% per year).

Croissance élevée des revenus: 002020's revenue (12.9% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 002020's Return on Equity is forecast to be low in 3 years time (12.8%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y